The Limitations of Antibiotic Incentives
This article was originally published in RPM Report
Executive Summary
Congress is on the verge of enacting important new incentives for antibiotic development. At the same time, a federal court ruling on Vancocin generic approvals underscores the importance of doing things the right way.